Skip To Main Content
Gwen Nichols on Muck Rack

Gwen Nichols

As seen in: Scientific American, STAT, Cell Press, Verywell Health, Healio, HemOnc Today, CURE Magazine, ONCOLOGY journal, Southwest Times Record, Targeted Oncology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gwen

Contact Gwen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Casdatifan Exhibits 1+ Year Survival in Later-Line Kidney Cancer

|
By Gwen Nichols, Roman Fabbricatore, Ariana Pelosci Verified
| ONCOLOGY journal Verified
Later-line treatment with the HIF-2α inhibitor casdatifan exhibited progression-free survival (PFS) exceeding 1 year among patients with metastatic clear cell renal cell carcinoma (ccRCC), according to findings from the phase 1/1b ARC-20 study.1 After a median follow-up of 17.9 months among 31 patients treated with a 100 mg daily dose of casdatifan, the median PFS was 15.1 months (95% CI, 5.7-not evaluable [NE]), with respective 6- and 12-month rates of 68% (95% CI, 48%-81%) and 61% (95% CI,...
Open in Who Shared Issue with article?

FDA Grants Fast Track Designation to ART6043/Olaparib in BRCA-Mutated, HER2– Breast Cancer | CancerNetwork

|
By Gwen Nichols, Ariana Pelosci Verified, Tim Cortese
| ONCOLOGY journal Verified
The FDA has granted fast track designation to ART6043 plus olaparib (Lynparza) for patients with germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer who have not received prior treatment with a PARP inhibitor, according to a press release from Artios Pharma Limited.1 ART6043 is a potentially first-in-class DNA polymerase θ inhibitor. The agent is an orally bioavailable and a small-molecule inhibitor.
Open in Who Shared Issue with article?

Gwen Nichols, MD

|
By Gwen Nichols
| ONCOLOGY journal Verified
Articles by Gwen Nichols, MD Data from the phase 3 Precision-T trial show improvements in overall survival and relapse-free survival with the use of Orca-T.
Open in Who Shared Issue with article?
See all 54 licensed articles (145 Total)